CRSP CRISPR Therapeutics AG
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1674416 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-34.3%
TTM net income YoY6.6%
TTM EPS YoY14.6%
Revenue 3-yr CAGR-47.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-2,114.8%
Net margin-1,812.1%
FCF margin-1,496.6%
EBITDA margin-2,041.3%
Returns
ROE-25.6%
ROA-19.0%
ROIC (approx.)-22.9%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets35.5%
Debt / equity0.36x
Current ratio16.21x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-3.4%
Payout ratio—
Capex / revenue8.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $3.51M | $37.31M |
| R&D expense | $284.81M | $310.24M |
| SG&A expense | $73.54M | $72.98M |
| Operating income | -$664.57M | -$466.57M |
| Pretax income | -$577.97M | -$362.67M |
| Income tax | $3.63M | $3.59M |
| Net income | -$581.60M | -$366.25M |
| EBITDA | -$645.09M | -$447.31M |
| EPS (basic) | -6.47 | -4.34 |
| EPS (diluted) | -6.47 | -4.34 |
| Weighted avg. shares (diluted) | 89.93M | 84.36M |
| Balance sheet | ||
| Cash & equivalents | $347.56M | $298.26M |
| Short-term investments | $1.63B | $1.61B |
| Receivables | $0 | $25.00M |
| Current assets | $1.99B | $1.94B |
| PP&E, net | $115.85M | $134.09M |
| Intangibles | — | $0 |
| Total assets | $2.27B | $2.24B |
| Current liabilities | $149.12M | $87.78M |
| Long-term debt | $0 | — |
| Total debt | $0 | — |
| Total liabilities | $343.43M | $309.95M |
| Shareholders' equity | $1.92B | $1.93B |
| Net debt | -$347.56M | — |
| Shares outstanding | 95.89M | 85.74M |
| Cash flow statement | ||
| Operating cash flow | -$345.01M | -$142.77M |
| Capital expenditure | $914,000 | $1.90M |
| Free cash flow | -$345.93M | -$144.68M |
| Investing cash flow | -$31.80M | -$280.48M |
| Financing cash flow | $426.03M | $331.98M |
| Depreciation & amortization | $19.48M | $19.26M |
| Stock-based compensation | $72.50M | $86.57M |
Free plan shows the latest 2 periods; Pro shows all 12 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.